Xeris Biopharma Holdings (XERS) Total Liabilities (2020 - 2026)

Xeris Biopharma Holdings has reported Total Liabilities for 7 years, with the latest figure at $379.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 8.11% year-over-year to $379.0 million; the trailing twelve-month figure through Mar 2026 stood at $379.0 million (up 8.11% YoY), and the FY2025 full-year result was $369.8 million, up 4.87% from the prior year.
• Total Liabilities for Q1 2026 stood at $379.0 million, up from $369.8 million in the prior quarter.
• The five-year high for Total Liabilities was $379.0 million in Q1 2026, with the low at $241.2 million in Q1 2022.
• Historically, Total Liabilities has averaged $324.5 million across 5 years, with a median of $345.8 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 1330.25% — and 2025, when it increased 0.85%.
• Xeris Biopharma Holdings' Total Liabilities stood at $299.3 million in 2022, then rose by 10.04% to $329.4 million in 2023, then grew by 7.07% to $352.7 million in 2024, then grew by 4.87% to $369.8 million in 2025, then grew by 2.48% to $379.0 million in 2026.
• The last three Total Liabilities figures came in at $379.0 million (Q1 2026), $369.8 million (Q4 2025), and $371.1 million (Q3 2025), per Business Quant data.